This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Gold, J. A.
Right arrow Articles by Weiden, M. D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Gold, J. A.
Right arrow Articles by Weiden, M. D.
Right arrowPubmed/NCBI databases
*Substance via MeSH

 Previous Article  |  Next Article 

Infection and Immunity, March 2004, p. 1291-1297, Vol. 72, No. 3
0019-9567/04/$08.00+0     DOI: 10.1128/IAI.72.3.1291-1297.2004
Copyright © 2004, American Society for Microbiology. All Rights Reserved.

Exogenous Gamma and Alpha/Beta Interferon Rescues Human Macrophages from Cell Death Induced by Bacillus anthracis

Jeffrey A. Gold,1 Yoshihiko Hoshino,1 Satomi Hoshino,1 Marcus B. Jones,2 Anna Nolan,1 and Michael D. Weiden1*

Division of Pulmonary and Critical Care Medicine,1 Department of Microbiology, Sackler Institute of Biomedical Studies, New York University School of Medicine, New York, New York 100162

Received 25 August 2003/ Returned for modification 14 October 2003/ Accepted 25 November 2003


arrow
ABSTRACT
 
During the recent bioterrorism-related outbreaks, inhalational anthrax had a 45% mortality in spite of appropriate antimicrobial therapy, underscoring the need for better adjuvant therapies. The variable latency between exposure and development of disease suggests an important role for the host's innate immune response. Alveolar macrophages are likely the first immune cells exposed to inhalational anthrax, and the interferon (IFN) response of these cells comprises an important arm of the host innate immune response to intracellular infection with Bacillus anthracis. Furthermore, IFNs have been used as immunoadjuvants for treatment of another intracellular pathogen, Mycobacterium tuberculosis. We established a model of B. anthracis infection with the Sterne strain (34F2) which contains lethal toxin (LeTx). 34F2 was lethal to murine and human macrophages. Treatment with IFNs significantly improved cell viability and reduced the number of germinated intracellular spores. Infection with 34F2 failed to induce the latent transcription factors signal transducer and activators of transcription 1 (STAT1) and ISGF-3, which are central to the IFN response. Furthermore, 34F2 reduced STAT1 activation in response to exogenous alpha/beta IFN, suggesting direct inhibition of IFN signaling. Even though 34F2 has LeTx, there was no mitogen-activated protein kinase kinase 3 cleavage and p38 was normally induced, suggesting that these early effects of B. anthracis infection in macrophages are independent of LeTx. These data suggest an important role for both IFNs in the control of B. anthracis and the potential benefit of using exogenous IFN as an immunoadjuvant therapy.


arrow
INTRODUCTION
 
Bacillus anthracis, a gram-positive, aerobic, spore-forming bacillus, is found ubiquitously in animals and soil. It causes a wide array of diseases in humans depending on the site of entry (31). When inhaled, B. anthracis causes mediastinal hemorrhage, pneumonia, and sepsis, with a high mortality in spite of appropriate therapy (23). Routine vaccination of animals and humans in animal husbandry had virtually eliminated this disease in the United States. Recently, anthrax gained renewed attention as a biowarfare agent. During the terrorist attacks of 2001, 11 people contracted inhalation anthrax, 11 contracted cutaneous anthrax, and hundreds of individuals were exposed to potentially dangerous levels of spores (23). In spite of widespread use of appropriate antibiotics, inhalation anthrax had a 45% mortality rate, underscoring the need for better adjuvant therapies in case of future attacks (23).

Virulence of B. anthracis is determined in part by its two megaplasmids, pXO1 and pXO2. pXO1, which is required for virulence, codes for the three components of B. anthracis toxins, lethal factor (LF), edema factor, and protective antigen. The majority of information learned about B. anthracis lethality has come from studies of lethal toxin (LeTx), a multimer of protective antigen and LF. LeTx is a zinc metallopeptidase which is highly lethal to resident macrophages. A major function of LeTx is proteolytic cleavage of mitogen-activated protein kinase kinase (MKK) family members in vitro and in vivo, resulting in defective p38 and extracellular signal-regulated kinase phosphorylation (11, 38). One consequence of this inhibition is attenuation of the host innate immune response. Cells treated with sublytic doses of LeTx have attenuated proinflammatory cytokine production in response to bacterial stimuli including LPS and B. anthracis cell wall components (12, 38, 40). However, the majority of data regarding LeTx is derived from studies with recombinant proteins administered to murine macrophages in vitro (12, 38, 40). Furthermore, while high levels of LeTx are observed during the late stages of infection, less is known about the extent of activity of LeTx during the early stages of infection with B. anthracis spores.

During the initial stages of inhalational anthrax, B. anthracis spores are taken up by alveolar macrophages (AM). Spores are able to survive in the phagolysosome and proceed to replicate intracellularly (22). This results in macrophage lysis and release of viable bacteria into the extracellular space. However, the time course for this is highly variable. Humans may not develop systemic disease until 43 days after exposure (30). Furthermore, viable spores have been found in mediastinal lymph nodes of infected monkeys up to 100 days after infection (21). Consequently, there may be numerous mechanisms important for control and destruction of intracellular spores.

The innate immune response is the primary means of pathogen control during the initial stages of infection. The interferon (IFN) system is an important component of innate immunity. There are two broad categories of IFN, alpha/beta IFN (IFN-{alpha}/ß) and gamma IFN (IFN-{gamma}). All IFNs signal via the janus kinase (JAK) and/or TYK kinases which phosphorylate and activate latent signal transducer and activators of transcription (STAT). Specifically, IFN-{gamma} leads to phosphorylation of STAT1 and formation of STAT1 homodimers that translocate to the nucleus and induce transcription by binding to gamma-activated sequences (GAS) in promoters of genes in the IFN response (47). IFN-{alpha}/ß leads to phosphorylation of STAT1 and STAT2, which then bind with IRF-9 to form ISGF-3 (13, 47). This heterotrimer translocates to the nucleus and binds ISRE sequences in promoters of IFN-responsive genes. Both IFN-{alpha}/ß and -{gamma} responses induce a large set of genes including a number of genes with antibacterial activity, including the inducible nitric oxide (NO) synthase gene (35). In addition, there are numerous JAK-STAT-independent mechanisms for both IFN signaling and production, including the p38 mitogen-activated protein kinase cascade (16, 28, 50).

IFN-{alpha}/ß was originally described in viral infections and plays a prominent role in inhibiting viral infection (26, 27, 43). However, IFN-{alpha}/ß is also involved during the initial stages of infection with intracellular pathogens. Macrophages infected with Mycobacterium tuberculosis induce an IFN-{alpha}/ß response within hours of infection (44, 52). There have been two trials of aerosolized IFN-{alpha} as an immunoadjuvant for pulmonary tuberculosis in humans (14). Treated subjects demonstrated earlier resolution of sputum cultures, earlier radiologic improvement, and reductions in cytokine levels in bronchoalveolar lavage fluid. Similar results were obtained in subjects with multidrug-resistant tuberculosis (15, 37).

In contrast, IFN-{gamma} is more prominent in the generation of Th-1 immunity. However, there is significant overlap in the activities of both IFN-{alpha}/ß and -{gamma}. IFN-{gamma} receptor knockout mice are highly susceptible to mycobacterial infection, as well as infection with other intracellular pathogens, including M. tuberculosis and Listeria monocytogenes (1, 6, 20, 29, 47). Furthermore, humans with congenital defects in IFN-{gamma} signaling are hypersusceptible to mycobacterial infections (32). As for IFN-{alpha}/ß, we have previously reported use of aerosolized IFN-{gamma} for the treatment of pulmonary tuberculosis. Treatment results in improved radiologic appearance, faster clearance of sputum cultures and activation of STAT1 in AM from treated subjects (4, 5).

Few data exist on the interaction between B. anthracis and the IFN system. Based on work with other pathogens, the intracellular nature of B. anthracis suggests a vital role for IFN-{alpha}/ß and -{gamma}. Furthermore, the ability of B. anthracis-derived toxins to modulate the host immune response suggests that B. anthracis, similar to other pathogens, may be capable of disrupting IFN signaling. Consequently, we sought to establish a B. anthracis infection model in human macrophages to determine whether exogenous IFN could affect cell survival. In addition, we wished to assess the ability of a LeTx+ strain of B. anthracis to inhibit IFN signaling.


arrow
MATERIALS AND METHODS
 
Cells. THP-1 cells (American Type Culture Collection) at a concentration of 5 x 105/ml were differentiated with 20 nM 12-O tetradecanoylphorbol 13-acetate (PMA) in Dulbecco's modified Eagle medium (DMEM) (BioWhittaker) with 10% fetal calf serum (FCS) (Life Technologies). Human AM were prepared as previously described (4, 52). Briefly, healthy volunteers underwent bronchoscopy with bronchoalveolar lavage with 100 ml of saline. Fluid was filtered to remove debris. Cells were spun at 800 x g for 5 min and resuspended in DMEM plus 10% fetal calf serum (FCS) at 5 x 105/ml.

Murine peritoneal macrophages (PM) were obtained as previously described. Briefly BALB/c mice were injected with 3% Brewer's thioglycolate (Sigma) for 3 to 5 days, after which mice were euthanized with CO2 and the peritoneal cavity of each mouse was lavaged with 10 ml of sterile saline. This results in >95% macrophages. Cells were washed and resuspended in DMEM-10% FCS at 5 x 105/ml.

Preparation of B. anthracis spores. The Sterne strain of B. anthracis spores (34F2; Colorado Serum Company), 9131 (pXO1- pXO2-; Insitut Pasteur), and RPL686 (pXO1+ pXO2-, {Delta}686; Insitut Pasteur) were prepared as previously described. Briefly, spores were allowed to germinate overnight at 37°C in phage assay broth (8 mg of Difco nutrient broth, 0.15 mg of CaCl2, 0.2 mg of MgSO4, 0.05 mg of MnSO4, 5 mg of NaCl, 10% horse serum). Flasks were then incubated at 30°C for 3 to 5 days. Spores were spun down and washed with sterile H2O four times. Spores were resuspended in sterile H2O and heat treated at 65°C for 30 min to kill any vegetative spores. Remaining spores were spun down and washed two times in sterile water and resuspended in sterile H2O at a concentration of 108/ml. Concentration was determined by quantitative cultures.

Infection and cell viability assays. Aliquots (100 µl) of macrophage suspension (prepared as described above) were plated in 96-well plates in DMEM plus 10% FCS (antibiotic free). B. anthracis spores were added for 30 min at the designated multiplicity of infection (MOI), after which time gentamicin (2.5 µg/ml; Gibco) was added to each well to kill any vegetative spores as in previously described protocols (10, 18). For experiments involving IFN, human recombinant IFN-{gamma} (Actimmune) or IFN-ß (R & D Systems) was added at the time of infection for the specified times and doses. Cell viability was determined by WST-1 assay (Roche) according to the manufacturer's instruction. Each experimental condition was run with five replicates. For trypan blue dye exclusion, cells were stained with 0.2% trypan blue and a total of 200 cells were counted. For quantitative cultures, cells were lysed with 0.1% Triton X-100 (Sigma) and 10-µl aliquots of lysates in serial dilutions were plated on blood agar plates at 37°C.

Transcription factor analysis. For analysis of transcription factor activity and cytokine production, experiments were repeated in 2.5-cm-diameter culture dishes (Falcon). Supernatant was collected at the designated time points, centrifuged at 800 x g for 10 min to remove cellular debris, and stored at -70°C till analysis. Cells were harvested and lysed as previously described (19, 52). Briefly, cells were harvested by gentle scraping and lysed in NP-40 lysis buffer (0.5% NP-40, 10% glycerol, 0.1 mM EDTA, 20 mM HEPES [pH 7.9], 10 mM NaF, 10 mM NaPi, 300 mM NaCl, aprotinin [3 µg/ml], leupeptin [2 µg/ml], pepstatin [2 µg/ml], 1 mM dithiothreitol, 1 mM phenylmethylsulfonyl fluoride, 1 mM Na3VO4) on ice for 30 min with vigorous agitation. Cells were centrifuged at 10,000 x g for 15 min, and supernatants were removed and stored for future analysis.

Immunoblots. Antibodies for ptyr701-STAT1, STAT1, p-p38, and total p38 were obtained from Cell Signal Technologies. Anti-MKK3 (C terminus) was obtained from Santa Cruz. Antibody for pser727-STAT1 was graciously provided by David Levy. For pser727-STAT1 immunoblots, cell lysates were first immunoprecipitated for STAT1. Briefly, equal amounts of protein (30 to 50 µg) were loaded onto a 10% polyacrylamide gel. After transfer to polyvinylidene difluoride, membranes were blocked in phosphate-buffered saline with 0.1% Tween and 5% milk, followed by overnight incubation at 4°C with primary antibody (anti-phospho-STAT1 or anti-STAT1 [Cell Signal Technology]). Membranes were developed with ECL Plus (Amersham). Images were scanned with a densitometer and bands quantified with ImageQuant software (Molecular Dynamics, Sunnyvale, Calif.).

Electrophoretic mobility shift assay (EMSA) for GAS and ISRE was performed according to the previously described protocol (4, 19, 25, 52). The GAS probe (5'-TACAACAGCCTGATTTCCCCGAAATGACGGC-3') and ISRE probe (5'-CTCGGGAAAGGGAAACCGAAACTGAAGCC-3') (the consensus binding region is indicated in boldface) were labeled with [{alpha}-32P]dCTP using Klenow DNA polymerase fill-in reaction. Full-length oligonucleotides were incubated with 10 µg of protein, 2.5 µg of poly(dI:dC), and gel shift buffer and run on a 4% polyacrylamide gel (Bio-Rad). For supershift reactions 1 µg of anti-STAT1 or anti-STAT2 (Cell Signal Technologies) was added to the mixture. Images were produced by a phosphorimager, and images were quantified with ImageQuant software.


arrow
RESULTS
 
Attenuated strains of B. anthracis are lethal to human macrophages. Previous reports demonstrate that the Sterne strain is lethal to murine macrophages (10, 18). We sought to extend these findings using transformed and primary human macrophages. This laboratory has observed that THP-1 cells differentiated with phorbol ester are an accurate model for human AM. Similar to previous investigators, we found that 34F2 reduced cell viability in murine PM in a dose-dependent manner, with a 30% reduction in viability at 4.5 h at an MOI of 20:1 (Fig. 1A) (10, 18). Furthermore, the Sterne variants RPL686, which has a point mutation in LF (pXO1+ pXO2- LF-), and 9131, which lacks both virulence plasmids (pXO1- pXO2-), had little effect on viability at this MOI (Fig. 1A). PMA-differentiated THP-1 cells had a similar response to infection with 34F2 (Fig. 1B). However, unlike murine cells, THP-1 cells were also susceptible to RPL686 (pXO1+ pXO2- LF-) at an MOI of 20:1 (Fig. 1B). Furthermore, there was a 20% reduction in viability in response to 9131 (pXO1-, pXO2-) compared to controls. Together, these results suggest differences between murine and human models of infections. As a result we conducted all subsequent experiments with human macrophages.



View larger version (23K):
[in this window]
[in a new window]
  		FIG. 1. Murine and human macrophages have differential sensitivities to different strains of B. anthracis. Murine PM (A) or PMA-differentiated THP-1 cells (B) were incubated with the Sterne strain (34F2), RPL686, or 9131 at an MOI of 20:1 for 4.5 h. Viability, relative to uninfected controls, was determined by WST-1 assay. Results represent three to five replicates. Error bars, standard errors of the means.

Exogenous IFN-{alpha}/ß and -{gamma} rescue macrophages from B. anthracis-induced lethality. Since IFN signaling may be disrupted by B. anthracis (38) we sought to determine if exogenous IFN could rescue cells from the lethality of B. anthracis. Human AM obtained from healthy volunteers and THP-1 macrophages showed similar mortalities after infection with 34F2. Treatment with IFN-{gamma} significantly improved cell viability, with a maximal effect at 400 U/ml (P = 0.009) (Fig. 2A). Similar results were obtained with IFN-ß at 1,000 U/ml (P = 0.03) (Fig. 2B). Results were confirmed with trypan blue dye exclusion (data not shown). IFN treatment also reduced mortality in B. anthracis-infected human peripheral blood mononuclear cells (data not shown). Together these data suggest that exogenous IFN-{alpha}/ß and -{gamma} improve cell viability during B. anthracis infection.



View larger version (16K):
[in this window]
[in a new window]
  		FIG. 2. Exogenous IFN-{alpha}/ß or -{gamma} improves viability in B. anthracis-infected macrophages. Human AM were incubated with the Sterne strain (34F2) with either IFN-ß at 1,000 U/ml (A), IFN-{gamma} at 400 U/ml (B), or saline at an MOI of 20:1 for 4.5 h. Viability was determined by WST-1 assay. Results are expressed as changes in viability relative to uninfected controls. Results represent 10 to 15 replicates. Error bars, standard deviations. *, P = 0.009; {blacklozenge}, P = 0.03.

We next sought to determine if IFN affected intracellular B. anthracis viability. Treatment with either IFN-{gamma} (140% of control) or IFN-ß (88% of control) had no effect on the total number of spores recovered from human AM at 4.5 h compared to untreated controls. Furthermore, neither IFN-{alpha}/ß nor IFN-{gamma} significantly affected the number of spores recovered at 30 min, indicating that IFN had little effect on phagocytosis (data not shown). The absence of a treatment effect was not surprising given the resistance of spores to killing by a number of noxious stimuli such as high temperature. Once spores are germinated, however, vegetative bacteria are no longer resistant to killing by heat. Therefore, incubation of infected macrophage lysates at 65°C will kill germinated bacteria but not ungerminated spores. IFN-{gamma} and IFN-ß reduced the fraction of germinated intracellular bacteria (P = 0.07 for IFN-ß) (Fig. 3). Similar results were obtained from THP-1 macrophages (data not shown). These data suggest that exogenous IFN are capable of increasing intracellular killing of germinated bacteria.



View larger version (45K):
[in this window]
[in a new window]
  		FIG. 3. Exogenous IFN-{alpha}/ß or -{gamma} reduces the number of germinated intracellular B. anthracis bacteria. Human AM or PMA-differentiated THP-1 macrophages were incubated with the Sterne strain (34F2) with either IFN-ß at 1,000 U/ml, IFN-{gamma} at 400 U/ml, or saline at an MOI of 20:1 for 4.5 h. Cells were lysed, and quantitative cultures were performed on lysate with or without heat treatment (65°C for 30 min). The fraction of germinated spores is the differential between culture results from non-heat-treated (total spores) and heat-treated lysate (ungerminated spores). Data represent three separate experiments. Error bars, standard deviations. *, P = 0.07.

Effect of B. anthracis on IFN signaling. We next wished to determine the effect of B. anthracis infection on IFN signaling. We used immunoblots probed with an antibody specific for phosphorylated STAT1 (ptyr701-STAT1) as a marker of IFN activity (47). Unlike M. tuberculosis, B. anthracis infection failed to induce ptyr701-STAT1 in human AM at 4.5 h (Fig. 4A, compare lanes 1 and 4) (44, 52). In contrast IFN-ß and IFN-{gamma} induced significant ptyr701-STAT1 (Fig. 4A, compare lane 1 with lanes 2 and 3). Infection with 34F2 inhibited the effect of IFN-ß on STAT1 phosphorylation in AM twofold (Fig. 4A, compare lanes 3 and 6). However, levels of ptyr701-STAT1 in IFN-ß-treated, 34F2-infected AM were still greater than unstimulated controls. In contrast, 34F2 had minimal effect on IFN-{gamma}-induced ptyr701-STAT1 formation (Fig. 4A, lanes 2 and 5). The alteration in ptyr701-STAT1 was not due to changes in the amount of total STAT1. Similar results were obtained when probing for serine phosphorylation of STAT1 (pser727-STAT1) (Fig. 4B). Similar data were obtained with murine PM (data not shown). These data suggest that B. anthracis inhibits IFN-{alpha}/ß signaling.



View larger version (44K):
[in this window]
[in a new window]
  		FIG. 4. B. anthracis inhibits IFN-{alpha}/ß signaling. Human macrophages were incubated with the Sterne strain (34F2) with either IFN-ß at 1,000 U/ml, IFN-{gamma} at 400 U/ml, or saline at an MOI of 20:1 for 4.5 h. (A) Immunoblot for ptyr701-STAT1 and total STAT1. Infection of human AM with 34F2 failed to induce ptyr701-STAT1 at 4.5 h (compare lanes 1 and 4) and reduced the degree of STAT1 phosphorylation by IFN-ß twofold compared to uninfected IFN-treated controls (compare lanes 3 and 6). 34F2 had a minimal effect on IFN-{gamma}-induced ptyr701-STAT1 formation (compare lanes 2 and 5). (B) Immunoblot for pser727-STAT1 and total STAT1 from STAT1-immunoprecipitated cell lysates. Infection of human THP-1 macrophages with 34F2 failed to induce pser727-STAT1 at 4.5 h (compare lanes 1 and 4) and reduced the degree of STAT1 phosphorylation by IFN-ß twofold compared to uninfected IFN-treated controls (compare lanes 3 and 6). 34F2 had a minimal effect on IFN-{gamma}-induced pser727-STAT1 formation (compare lanes 2 and 5). (C) EMSA for ISGF-3. Infection of human AM with 34F2 failed to induce ISGF-3 DNA binding at 4.5 h (compare lanes 1 and 3) and inhibited IFN-ß-induced ISGF-3 production (compare lanes 2 and 4). This band was confirmed to be ISGF-3 in a separate experiment by both cold competition (lane 6) and supershift with antibodies to STAT1, STAT2, and IRF-9 (lanes 7 to 9). (D) EMSA for STAT1 homodimer (GAS binding). IFN-{gamma} induced STAT1 homodimer formation (lane 2), which was unaffected by infection of human AM with 34F2 (lane 5). This complex was supershifted with STAT1 antibody (lane 3). In all cases lanes were normalized for total protein.

To confirm the results of the immunoblot, we used EMSA with an ISRE containing oligonucleotide to determine whether the changes in ptyr701-STAT1 produced alterations in DNA binding activity of ISGF-3, the heterotrimer of STAT1, STAT2, and IRF-9. As predicted by the results of the immunoblot, infection with 34F2 inhibited ISGF-3 formation in response to IFN-ß (Fig. 4C, lanes 2 and 4). Also, infected AM failed to induce ISGF-3 at 4.5 h (Fig. 4C, lane 3) or at 20 h (data not shown). The identity of ISGF-3 was confirmed by both cold competition (Fig. 4C, lane 6) and supershift with antibodies to STAT1, STAT2, and IRF-9 (Fig. 4C, lanes 7 to 9). To assay the IFN-{gamma} effect, EMSA was performed with oligonucleotide containing a GAS sequence. STAT1 homodimer formation in response to IFN-{gamma} was unaffected by infection (Fig. 4D, lanes 2 and 5). Supershift with STAT1 antibody (Fig. 4D, lane 3) and cold competition with GAS oligonucleotide (data not shown) confirmed the identity of this DNA-protein complex. Together, these data suggest that infection with the Sterne strain is capable of inhibition of IFN-{alpha}/ß but not IFN-{gamma} signaling.

We next sought to determine whether LeTx was active at this early point in infection. The main target of LeTx in macrophages is the MKK family members including MKK3 (38). LeTx cleaves and inactivates MKK-3. Formation of MKK-3 cleavage products is highly sensitive for LeTx activity (11, 38). Infection of AM with 34F2 (LF+) did not produce MKK3 cleavage. In fact, there was an increase in total MKK3 after infection with 34F2 (Fig. 5A). Similar results were obtained with murine PM (data not shown). The principal target of MKK3 is phosphorylation of p38 (p-p38). As predicted from the increased MMK-3, infection produced a threefold increase in p38 phosphorylation (Fig. 5B). In all cases lanes were normalized for total protein and there was no change in total p38. Together these data indicate that the metallopeptidase activity of LeTx is not active at these early time points and therefore 34F2 kills AM and inhibits IFN signaling by other mechanisms.



View larger version (23K):
[in this window]
[in a new window]
  		FIG. 5. Infection with B. anthracis is not associated with MKK3 cleavage at 4.5 h. Human AM were incubated with the Sterne strain (34F2) at an MOI of 20:1 for 4.5 h. (A) Immunoblot for MKK3. Infection with 34F2 is associated with increased MKK3. (B) Immunoblot for phosphorylated and total p38. Infection with 34F2 is associated with increased p38 phosphorylation. All lanes were normalized for protein.


arrow
DISCUSSION
 
In this study, we demonstrated that the Sterne strain of B. anthracis is lethal to human AM. This lethality can be modulated by both exogenous IFN-{alpha}/ß and IFN-{gamma}, possibly by reducing the number of germinated intracellular bacteria. Infection with B. anthracis also fails to induce an IFN-{alpha}/ß response, as evidenced by defective ptyr701-STAT1 and pser727-STAT1 induction and subsequent ISGF-3 formation. It is likely that this is in part due to inhibition of IFN-{alpha}/ß signaling by B. anthracis. This inhibition of IFN signaling is not due to LeTx metallopeptidase activity, suggesting a LeTx-independent mechanism for inhibiting the innate immune response in macrophages.

Currently few data exist on the interaction between B. anthracis and human AM, the primary target of inhalational anthrax. Our data suggest that human macrophages and murine PM are equally susceptible to infection with the Sterne strain of B. anthracis. The similar responses of primary human AM and THP-1 macrophages reconfirm our previous observation that THP-1 macrophages provide a good model for human AM (52). The lack of susceptibility of murine PM to other attenuated strains of B. anthracis, 9131 and RPL686, is in accord with previous investigations (18). Surprisingly, these strains were still lethal to human macrophages, suggesting some interspecies differences in response to B. anthracis. This underscores the importance of confirming existing murine data in human macrophages.

The ability of both IFN-{alpha}/ß and IFN-{gamma} to rescue cells from the lethality of B. anthracis is surprising. As viability data were normalized for IFN-treated, noninfected cells, this effect is not due to an independent effect of IFN on viability. While IFN did improve macrophage viability, it is unclear whether this is due to changes in apoptosis, lysis or both. As both B. anthracis LeTx and IFN themselves are capable of inducing apoptosis, this needs to be addressed by further studies (2, 9, 10, 17, 41).

While the mechanism by which IFN improves cell viability remains unclear, one possibility is that IFN reduces the intracellular burden of B. anthracis. Our data suggest that IFNs are capable of inhibiting intracellular germination of B. anthracis. As spore germination is required for production of toxins and other proteins required for cell death, this could certainly explain the improvement in macrophage viability. The mechanism by which IFN impairs germination remains unclear. One possibility is increased activation of the host innate immune response. IFN-{alpha}/ß and IFN-{gamma} increase production of NO and reactive oxygen species which are essential to the host control of intracellular pathogens including M. tuberculosis (3, 8, 35). Conversely, IFN could directly inhibit bacterial germination and/or growth factors. The recent identification of gerS and atxA1 as pivotal for germination and bacterial release, respectively, provides additional targets for investigation (10, 22).

The protective effect of IFN in vitro suggests that B. anthracis may modulate the host IFN response to facilitate its own survival. The lack of pser727- and ptyr701-STAT1 formation and ISGF-3 DNA binding activity in B. anthracis-infected cells indicates that B. anthracis inhibits the generation of an IFN-{alpha}/ß response. The induction of IFN-{alpha}/ß and subsequent signaling in macrophages are observed during infection with numerous intracellular pathogens, including M. tuberculosis and Bacillus subtilis, a family member of B. anthracis, as early as 3 h after infection (36, 44, 52). The lack of IFN-{alpha}/ß signaling in our study may be the result of impaired IFN-{alpha}/ß production and/or inhibition of IFN signaling. However, the ability of B. anthracis to attenuate signaling by exogenous IFN-{alpha}/ß suggests that direct inhibition of IFN signaling is partially responsible for this observation. This observation is not unique. Previous investigators reported that B. anthracis LeTx inhibition of IFN-{gamma} induced NO production from murine macrophages although they did not describe the means of this inhibition (38). Furthermore, multiple studies document that M. tuberculosis also inhibits IFN-{alpha}/ß signaling, both at the level of STAT1 phosphorylation and transcriptional activation (42, 49).

The mechanism of B. anthracis inhibition of IFN-{alpha}/ß signaling in our study remains unclear. The finding of impaired ptyr701-STAT1 and pser727-STAT1 formation suggests that multiple pathways may be affected. Inhibition of IFN-{alpha}/ß-induced ptyr701-STAT1 formation suggests inhibition of either the IFN-{alpha}/ß receptor or the downstream kinases JAK1 or Tyk2. This may be either direct inhibition, the result of upregulation of endogenous inhibitors such as suppressors of cytokine signaling, or increased phosphatase activity (7, 24, 39).

Formation of pser727-STAT1 is a JAK-independent means of STAT1 activation and is essential for nuclear translocation of STAT1-containing transcription factors and subsequent promoter-enhancing activity (53). The mechanism of pser727-STAT1 inhibition is also unclear. Studies suggest that inhibition of p38 can abolish pser727-STAT1 formation in response to IFN-{alpha}/ß (48). However, the lack of MKK3 cleavage and slight increase in p38 phosphorylation during infection of a LeTx-competent strain of B. anthracis suggests that this inhibition is independent of the proteolytic effects of LeTx. This is not surprising, as other investigators have demonstrated that cleavage of MKK family members, a highly sensitive indicator of LeTx activity, is not responsible for LeTx cytolysis. Macrophages from LeTx-resistant mice manifest levels of MKK cleavage similar to those manifested by LeTx-susceptible strains, suggesting other biologic effects (46, 51). Furthermore, the vast majority of studies investigating the effects of LeTx on intracellular signaling have utilized recombinant proteins. While more specific for LeTx activity, they utilize levels of toxin which may be manyfold higher than what is observed during the early stages of intracellular infection. This implicates the presence of other non-LeTx-mediated mechanisms of cell death during the early stages of infection with live spores. Together our data suggest that inhibition of pser727-STAT1 formation in this model lies either distal to p38 activation or involves p38-independent signaling intermediates such as IRAK, MYD88, or phosphatidylinositol 3-kinase (33, 34, 45).

In conclusion, this study provides important data regarding the role of B. anthracis infection on human AM, the primary target of inhalational anthrax. By demonstrating that B. anthracis is capable of altering IFN signaling in vitro and exogenous IFNs are capable of overcoming this inhibition and rescuing infected macrophages, we now suggest a potential role for exogenous IFN as an immunoadjuvant in vivo.


arrow
ACKNOWLEDGMENTS
 
This work was supported by NIH NCRR GCRC MO1 RR0096, ALA Career Investigator Award, K08 HL070710, RO1 HL57879, UNCF/MERCK Graduate Science Research Dissertation Fellowship, the David and Lucile Packard Foundation, and RO1 GM 63270.


arrow
FOOTNOTES
 
* Corresponding author. Mailing address: Division of Pulmonary and Critical Care Medicine, New York University School of Medicine, New Bellevue Hospital, Room 7N24, 27th St. and First Ave., New York, NY 10016. Phone: (212) 263-7889. Fax: (212) 263-8442. E-mail: Weidem01{at}gcrc.med.nyu.edu. Back

Editor: A. D. O'Brien


arrow
REFERENCES
 
    1
  1. Anthony, L. S., E. Ghadirian, F. P. Nestel, and P. A. Kongshavn. 1989. The requirement for gamma interferon in resistance of mice to experimental tularemia. Microb. Pathog. 7:421-428.[CrossRef][Medline]
    2. 2
  2. Buschle, M., D. Campana, S. R. Carding, C. Richard, A. V. Hoffbrand, and M. K. Brenner. 1993. Interferon gamma inhibits apoptotic cell death in B cell chronic lymphocytic leukemia. J. Exp. Med. 177:213-218.[Abstract/Free Full Text]
    3. 3
  3. Chan, J., Y. Xing, R. S. Magliozzo, and B. R. Bloom. 1992. Killing of virulent Mycobacterium tuberculosis by reactive nitrogen intermediates produced by activated murine macrophages. J. Exp. Med. 175:1111-1122.[Abstract/Free Full Text]
    4. 4
  4. Condos, R., B. Raju, A. Canova, M. Zhao, M. Weiden, W. N. Rom, and R. Pine. 2002. Recombinant gamma interferon stimulates signal transduction and gene expression in alveolar macrophages in vitro and in tuberculosis patients. Infect. Immun. 71:2058-2064.
    5. 5
  5. Condos, R., W. N. Rom, and N. W. Schluger. 1997. Treatment of multidrug-resistant pulmonary tuberculosis with interferon-gamma via aerosol. Lancet 349:1513-1515.[CrossRef][Medline]
    6. 6
  6. Dalton, D. K., S. Pitts-Meek, S. Keshav, I. S. Figari, A. Bradley, and T. A. Stewart. 1993. Multiple defects of immune cell function in mice with disrupted interferon-gamma genes. Science 259:1739-1742.[Abstract/Free Full Text]
    7. 7
  7. David, M., H. E. Chen, S. Goelz, A. C. Larner, and B. G. Neel. 1995. Differential regulation of the alpha/beta interferon-stimulated Jak/Stat pathway by the SH2 domain-containing tyrosine phosphatase SHPTP1. Mol. Cell. Biol. 15:7050-7058.[Abstract]
    8. 8
  8. Denis, M. 1991. Interferon-gamma-treated murine macrophages inhibit growth of tubercle bacilli via the generation of reactive nitrogen intermediates. Cell. Immunol. 132:150-157.[CrossRef][Medline]
    9. 9
  9. Der, S. D., Y. L. Yang, C. Weissmann, and B. R. Williams. 1997. A double-stranded RNA-activated protein kinase-dependent pathway mediating stress-induced apoptosis. Proc. Natl. Acad. Sci. USA 94:3279-3283.[Abstract/Free Full Text]
    10. 10
  10. Dixon, T. C., A. A. Fadl, T. M. Koehler, J. A. Swanson, and P. C. Hanna. 2000. Early Bacillus anthracis-macrophage interactions: intracellular survival and escape. Cell. Microbiol. 2:453-463.[CrossRef][Medline]
    11. 11
  11. Duesbery, N. S., C. P. Webb, S. H. Leppla, V. M. Gordon, K. R. Klimpel, T. D. Copeland, N. G. Ahn, M. K. Oskarsson, K. Fukasawa, K. D. Paull, and G. F. Vande Woude. 1998. Proteolytic inactivation of MAP-kinase-kinase by anthrax lethal factor. Science 280:734-737.[Abstract/Free Full Text]
    12. 12
  12. Erwin, J. L., L. M. DaSilva, S. Bavari, S. F. Little, A. M. Friedlander, and T. C. Chanh. 2001. Macrophage-derived cell lines do not express proinflammatory cytokines after exposure to Bacillus anthracis lethal toxin. Infect. Immun. 69:1175-1177.[Abstract/Free Full Text]
    13. 13
  13. Fu, X. Y., D. S. Kessler, S. A. Veals, D. E. Levy, and J. E. Darnell, Jr. 1990. ISGF3, the transcriptional activator induced by interferon alpha, consists of multiple interacting polypeptide chains. Proc. Natl. Acad. Sci. USA 87:8555-8559.[Abstract/Free Full Text]
    14. 14
  14. Giosue, S., M. Casarini, L. Alemanno, G. Galluccio, P. Mattia, G. Pedicelli, L. Rebek, A. Bisetti, and F. Ameglio. 1998. Effects of aerosolized interferon-alpha in patients with pulmonary tuberculosis. Am. J. Respir. Crit. Care Med. 158:1156-1162.[Abstract/Free Full Text]
    15. 15
  15. Giosue, S., M. Casarini, F. Ameglio, P. Zangrilli, M. Palla, A. M. Altieri, and A. Bisetti. 2000. Aerosolized interferon-alpha treatment in patients with multi-drug-resistant pulmonary tuberculosis. Eur. Cytokine Netw. 11:99-104.[Medline]
    16. 16
  16. Goh, K. C., S. J. Haque, and B. R. Williams. 1999. p38 MAP kinase is required for STAT1 serine phosphorylation and transcriptional activation induced by interferons. EMBO J. 18:5601-5608.[CrossRef][Medline]
    17. 17
  17. Grawunder, U., F. Melchers, and A. Rolink. 1993. Interferon-gamma arrests proliferation and causes apoptosis in stromal cell/interleukin-7-dependent normal murine pre-B cell lines and clones in vitro, but does not induce differentiation to surface immunoglobulin-positive B cells. Eur. J. Immunol. 23:544-551.[Medline]
    18. 18
  18. Guidi-Rontani, C., M. Levy, H. Ohayon, and M. Mock. 2001. Fate of germinated Bacillus anthracis spores in primary murine macrophages. Mol. Microbiol. 42:931-938.[CrossRef][Medline]
    19. 19
  19. Hoshino, Y., K. Nakata, S. Hoshino, Y. Honda, D. B. Tse, T. Shioda, W. N. Rom, and M. Weiden. 2002. Maximal HIV-1 replication in alveolar macrophages during tuberculosis requires both lymphocyte contact and cytokines. J. Exp. Med. 195:495-505.[Abstract/Free Full Text]
    20. 20
  20. Huang, S., W. Hendriks, A. Althage, S. Hemmi, H. Bluethmann, R. Kamijo, J. Vilcek, R. M. Zinkernagel, and M. Aguet. 1993. Immune response in mice that lack the interferon-gamma receptor. Science 259:1742-1745.[Abstract/Free Full Text]
    21. 21
  21. Inglesby, T. V., T. O'Toole, D. A. Henderson, J. G. Bartlett, M. S. Ascher, E. Eitzen, A. M. Friedlander, J. Gerberding, J. Hauer, J. Hughes, J. McDade, M. T. Osterholm, G. Parker, T. M. Perl, P. K. Russell, and K. Tonat. 2002. Anthrax as a biological weapon, 2002: updated recommendations for management. JAMA 287:2236-2252.[Abstract/Free Full Text]
    22. 22
  22. Ireland, J. A., and P. C. Hanna. 2002. Macrophage-enhanced germination of Bacillus anthracis endospores requires gerS. Infect. Immun. 70:5870-5872.[Abstract/Free Full Text]
    23. 23
  23. Jernigan, D. B., P. L. Raghunathan, B. P. Bell, R. Brechner, E. A. Bresnitz, J. C. Butler, M. Cetron, M. Cohen, T. Doyle, M. Fischer, C. Greene, K. S. Griffith, J. Guarner, J. L. Hadler, J. A. Hayslett, R. Meyer, L. R. Petersen, M. Phillips, R. Pinner, T. Popovic, C. P. Quinn, J. Reefhuis, D. Reissman, N. Rosenstein, A. Schuchat, W. J. Shieh, L. Siegal, D. L. Swerdlow, F. C. Tenover, M. Traeger, J. W. Ward, I. Weisfuse, S. Wiersma, K. Yeskey, S. Zaki, D. A. Ashford, B. A. Perkins, S. Ostroff, J. Hughes, D. Fleming, J. P. Koplan, and J. L. Gerberding. 2002. Investigation of bioterrorism-related anthrax, United States, 2001: epidemiologic findings. Emerg. Infect. Dis. 8:1019-1028.[Medline]
    24. 24
  24. Krebs, D. L., and D. J. Hilton. 2001. SOCS proteins: negative regulators of cytokine signaling. Stem Cells 19:378-387.[CrossRef][Medline]
    25. 25
  25. Lee, C. K., R. Raz, R. Gimeno, R. Gertner, B. Wistinghausen, K. Takeshita, R. A. DePinho, and D. E. Levy. 2002. STAT3 is a negative regulator of granulopoiesis but is not required for G-CSF-dependent differentiation. Immunity 17:63-72.[CrossRef][Medline]
    26. 26
  26. Levy, D. E., and A. Garcia-Sastre. 2001. The virus battles: IFN induction of the antiviral state and mechanisms of viral evasion. Cytokine Growth Factor Rev. 12:143-156.[CrossRef][Medline]
    27. 27
  27. Levy, D. E., I. Marie, E. Smith, and A. Prakash. 2002. Enhancement and diversification of IFN induction by IRF-7-mediated positive feedback. J. Interferon Cytokine Res. 22:87-93.[CrossRef][Medline]
    28. 28
  28. Lu, H. T., D. D. Yang, M. Wysk, E. Gatti, I. Mellman, R. J. Davis, and R. A. Flavell. 1999. Defective IL-12 production in mitogen-activated protein (MAP) kinase kinase 3 (Mkk3)-deficient mice. EMBO J. 18:1845-1857.[CrossRef][Medline]
    29. 29
  29. Meraz, M. A., J. M. White, K. C. Sheehan, E. A. Bach, S. J. Rodig, A. S. Dighe, D. H. Kaplan, J. K. Riley, A. C. Greenlund, D. Campbell, K. Carver-Moore, R. N. DuBois, R. Clark, M. Aguet, and R. D. Schreiber. 1996. Targeted disruption of the Stat1 gene in mice reveals unexpected physiologic specificity in the JAK-STAT signaling pathway. Cell 84:431-442.[CrossRef][Medline]
    30. 30
  30. Meselson, M., J. Guillemin, M. Hugh-Jones, A. Langmuir, I. Popova, A. Shelokov, and O. Yampolskaya. 1994. The Sverdlovsk anthrax outbreak of 1979. Science 266:1202-1208.[Abstract/Free Full Text]
    31. 31
  31. Mock, M., and A. Fouet. 2001. Anthrax. Annu. Rev. Microbiol. 55:647-671.[CrossRef][Medline]
    32. 32
  32. Newport, M. J., C. M. Huxley, S. Huston, C. M. Hawrylowicz, B. A. Oostra, R. Williamson, and M. Levin. 1996. A mutation in the interferon-gamma-receptor gene and susceptibility to mycobacterial infection. N. Engl. J. Med. 335:1941-1949.[Abstract/Free Full Text]
    33. 33
  33. Nguyen, H., M. Chatterjee-Kishore, Z. Jiang, Y. Qing, C. V. Ramana, J. Bayes, M. Commane, X. Li, and G. R. Stark. 2003. IRAK-dependent phosphorylation of Stat1 on serine 727 in response to interleukin-1 and effects on gene expression. J. Interferon Cytokine Res. 23:183-192.[CrossRef][Medline]
    34. 34
  34. Nguyen, H., C. V. Ramana, J. Bayes, and G. R. Stark. 2001. Roles of phosphatidylinositol 3-kinase in interferon-gamma-dependent phosphorylation of STAT1 on serine 727 and activation of gene expression. J. Biol. Chem. 276:33361-33368.[Abstract/Free Full Text]
    35. 35
  35. Nunokawa, Y., N. Ishida, and S. Tanaka. 1994. Promoter analysis of human inducible nitric oxide synthase gene associated with cardiovascular homeostasis. Biochem. Biophys. Res. Commun. 200:802-807.[CrossRef][Medline]
    36. 36
  36. O'Riordan, M., C. H. Yi, R. Gonzales, K. D. Lee, and D. A. Portnoy. 2002. Innate recognition of bacteria by a macrophage cytosolic surveillance pathway. Proc. Natl. Acad. Sci. USA 99:13861-13866.[Abstract/Free Full Text]
    37. 37
  37. Palmero, D., K. Eiguchi, P. Rendo, L. Castro Zorrilla, E. Abbate, and L. J. Gonzalez Montaner. 1999. Phase II trial of recombinant interferon-alpha2b in patients with advanced intractable multidrug-resistant pulmonary tuberculosis: long-term follow-up. Int. J. Tuberc. Lung Dis. 3:214-218.[Medline]
    38. 38
  38. Pellizzari, R., C. Guidi-Rontani, G. Vitale, M. Mock, and C. Montecucco. 1999. Anthrax lethal factor cleaves MKK3 in macrophages and inhibits the LPS/IFN{gamma}-induced release of NO and TNF{alpha}. FEBS Lett. 462:199-204.[CrossRef][Medline]
    39. 39
  39. Petricoin, E., III, M. David, K. Igarashi, C. Benjamin, L. Ling, S. Goelz, D. S. Finbloom, and A. C. Larner. 1996. Inhibition of alpha interferon but not gamma interferon signal transduction by phorbol esters is mediated by a tyrosine phosphatase. Mol. Cell. Biol. 16:1419-1424.[Abstract]
    40. 40
  40. Popov, S. G., R. Villasmil, J. Bernardi, E. Grene, J. Cardwell, T. Popova, A. Wu, D. Alibek, C. Bailey, and K. Alibek. 2002. Effect of Bacillus anthracis lethal toxin on human peripheral blood mononuclear cells. FEBS Lett. 527:211-215.[CrossRef][Medline]
    41. 41
  41. Popov, S. G., R. Villasmil, J. Bernardi, E. Grene, J. Cardwell, A. Wu, D. Alibek, C. Bailey, and K. Alibek. 2002. Lethal toxin of Bacillus anthracis causes apoptosis of macrophages. Biochem. Biophys. Res. Commun. 293:349-355.[CrossRef][Medline]
    42. 42
  42. Prabhakar, S., Y. Qiao, Y. Hoshino, M. Weiden, A. Canova, i. E. Giacomin, E. Coccia, and R. Pine. 2003. Inhibition of response to alpha interferon by Mycobacterium tuberculosis. Infect. Immun. 71:2487-2497.[Abstract/Free Full Text]
    43. 43
  43. Reich, N., R. Pine, D. Levy, and J. E. Darnell, Jr. 1988. Transcription of interferon-stimulated genes is induced by adenovirus particles but is suppressed by E1A gene products. J. Virol. 62:114-119.[Abstract/Free Full Text]
    44. 44
  44. Remoli, M. E., E. Giacomini, G. Lutfalla, E. Dondi, G. Orefici, A. Battistini, G. Uze, S. Pellegrini, and E. M. Coccia. 2002. Selective expression of type I IFN genes in human dendritic cells infected with Mycobacterium tuberculosis. J. Immunol. 169:366-374.[Abstract/Free Full Text]
    45. 45
  45. Rhee, S. H., B. W. Jones, V. Toshchakov, S. N. Vogel, and M. J. Fenton. 2003. Toll-like receptors 2 and 4 activate STAT1 serine phosphorylation by distinct mechanisms in macrophages. J. Biol. Chem. 278:22506-22512.[Abstract/Free Full Text]
    46. 46
  46. Roberts, J. E., J. W. Watters, J. D. Ballard, and W. F. Dietrich. 1998. Ltx1, a mouse locus that influences the susceptibility of macrophages to cytolysis caused by intoxication with Bacillus anthracis lethal factor, maps to chromosome 11. Mol. Microbiol. 29:581-591.[CrossRef][Medline]
    47. 47
  47. Stark, G. R., I. M. Kerr, B. R. Williams, R. H. Silverman, and R. D. Schreiber. 1998. How cells respond to interferons. Annu. Rev. Biochem. 67:227-264.[CrossRef][Medline]
    48. 48
  48. Stoiber, D., S. Stockinger, P. Steinlein, J. Kovarik, and T. Decker. 2001. Listeria monocytogenes modulates macrophage cytokine responses through STAT serine phosphorylation and the induction of suppressor of cytokine signaling 3. J. Immunol. 166:466-472.[Abstract/Free Full Text]
    49. 49
  49. Ting, L. M., A. C. Kim, A. Cattamanchi, and J. D. Ernst. 1999. Mycobacterium tuberculosis inhibits IFN-gamma transcriptional responses without inhibiting activation of STAT1. J. Immunol. 163:3898-3906.[Abstract/Free Full Text]
    50. 50
  50. Uddin, S., B. Majchrzak, J. Woodson, P. Arunkumar, Y. Alsayed, R. Pine, P. R. Young, E. N. Fish, and L. C. Platanias. 1999. Activation of the p38 mitogen-activated protein kinase by type I interferons. J. Biol. Chem. 274:30127-30131.[Abstract/Free Full Text]
    51. 51
  51. Watters, J. W., K. Dewar, J. Lehoczky, V. Boyartchuk, and W. F. Dietrich. 2001. Kif1C, a kinesin-like motor protein, mediates mouse macrophage resistance to anthrax lethal factor. Curr. Biol. 11:1503-1511.[CrossRef][Medline]
    52. 52
  52. Weiden, M., N. Tanaka, Y. Qiao, B. Y. Zhao, Y. Honda, K. Nakata, A. Canova, D. E. Levy, W. N. Rom, and R. Pine. 2000. Differentiation of monocytes to macrophages switches the Mycobacterium tuberculosis effect on HIV-1 replication from stimulation to inhibition: modulation of interferon response and CCAAT/enhancer binding protein beta expression. J. Immunol. 165:2028-2039.[Abstract/Free Full Text]
    53. 53
  53. Wen, Z., Z. Zhong, and J. E. Darnell, Jr. 1995. Maximal activation of transcription by Stat1 and Stat3 requires both tyrosine and serine phosphorylation. Cell 82:241-250.[CrossRef][Medline]

Infection and Immunity, March 2004, p. 1291-1297, Vol. 72, No. 3
0019-9567/04/$08.00+0     DOI: 10.1128/IAI.72.3.1291-1297.2004
Copyright © 2004, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:

  • Wu, W., Mehta, H., Chakrabarty, K., Booth, J. L., Duggan, E. S., Patel, K. B., Ballard, J. D., Coggeshall, K. M., Metcalf, J. P. (2009). Resistance of Human Alveolar Macrophages to Bacillus anthracis Lethal Toxin. J. Immunol. 183: 5799-5806 [Abstract] [Full Text]  
  • Crawford, M. A., Zhu, Y., Green, C. S., Burdick, M. D., Sanz, P., Alem, F., O'Brien, A. D., Mehrad, B., Strieter, R. M., Hughes, M. A. (2009). Antimicrobial Effects of Interferon-Inducible CXC Chemokines against Bacillus anthracis Spores and Bacilli. Infect. Immun. 77: 1664-1678 [Abstract] [Full Text]  
  • Qiu, H., Fan, Y., Joyee, A. G., Wang, S., Han, X., Bai, H., Jiao, L., Van Rooijen, N., Yang, X. (2008). Type I IFNs Enhance Susceptibility to Chlamydia muridarum Lung Infection by Enhancing Apoptosis of Local Macrophages. J. Immunol. 181: 2092-2102 [Abstract] [Full Text]  
  • Glomski, I. J., Corre, J.-P., Mock, M., Goossens, P. L. (2007). Cutting Edge: IFN-{gamma}-Producing CD4 T Lymphocytes Mediate Spore-Induced Immunity to Capsulated Bacillus anthracis. J. Immunol. 178: 2646-2650 [Abstract] [Full Text]  
  • Bergman, N. H., Passalacqua, K. D., Gaspard, R., Shetron-Rama, L. M., Quackenbush, J., Hanna, P. C. (2005). Murine Macrophage Transcriptional Responses to Bacillus anthracis Infection and Intoxication. Infect. Immun. 73: 1069-1080 [Abstract] [Full Text]  
  • Barth, H., Aktories, K., Popoff, M. R., Stiles, B. G. (2004). Binary Bacterial Toxins: Biochemistry, Biology, and Applications of Common Clostridium and Bacillus Proteins. Microbiol. Mol. Biol. Rev. 68: 373-402 [Abstract] [Full Text]  

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Gold, J. A.
Right arrow Articles by Weiden, M. D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Gold, J. A.
Right arrow Articles by Weiden, M. D.
Right arrowPubmed/NCBI databases
*Substance via MeSH

Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»